ISSN Print 2500–1094
ISSN Online 2542–1204
BIOMEDICAL JOURNAL OF PIROGOV UNIVERSITY (MOSCOW, RUSSIA)
Copyright: © 2025 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
ORIGINAL RESEARCH
Assessment of the features of innate lymphoid cells in patients with multiple myeloma
About authors
1 Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia
2 Faculty of Medicine, Novosibirsk State Medical University, Novosibirsk, Russia
Correspondence should be addressed: Ekaterina A. Pashkina
Yadrintsevskaya, 14, Novosibirsk, 630099, Russia; ur.xednay@a.e.anikhsap
About paper
Funding: financial support from the Government of the Novosibirsk Region, Agreement #ML-1 of October 26, 2023.
Author contribution: Pashkina EA, Denisova VV — study planning and design, Denisova VV — selection of participants, collection of clinical data; Borisevich VI, Abbasova VS, Skachkov IP, Lazarev YaA — data collection and study execution; Pashkina EA, Boeva OS — data analysis and interpretation, manuscript drafting; Pashkina EA — text editing.
Compliance with ethical standards: the study was approved by the Ethics Committee of the Research Institute of Fundamental and Clinical Immunology (Minutes #145 of April 19, 2024). All participants signed the voluntary informed consent form.
Received: 2024-12-02
Accepted: 2025-02-14
Published online: 2025-02-25
|
Fig. 1. The relative amount of ILC in the total PB MNC, MM patients and conditionally healthy individuals
Fig. 2. The relative amount of ILC2 in the total PB MNC, MM patients and conditionally healthy individuals
Fig. 3. The relative amount of ILC1 in the total PB MNC, MM patients and conditionally healthy individuals
Fig. 4. The relative amount of ILC3 in the total PB MNC, MM patients and conditionally healthy individuals
Fig. 5. The relative amount of ILC2 in the total number of ILC, MM patients and conditionally healthy individuals
Fig. 6. The relative amount of HLA-DR+ILLC2 in the total number of ILC2, MM patients and conditionally healthy individuals
